Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v6-EN
Language English English
Date Updated 2022-05-15 2022-03-08
Drug Identification Number 02139529 02139529
Brand name SODIUM ACETATE INJECTION, USP SODIUM ACETATE INJECTION, USP
Common or Proper name Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients SODIUM ACETATE SODIUM ACETATE
Strength(s) 328MG 328MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 50 mL 50 mL
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2021-12-17 2021-12-17
Estimated end date Unknown 2022-03-15
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments On backorder. Effective May 16, 2022 - July 31, 2022, contract customers will be allocated 100% of 50mL demand on mL:mL basis using the 100mL format. Fresenius Kabi Canada regrets to advise that due to unforeseen circumstances, we will be encountering a supply interruption, effective immediately, on our Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL and Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL.
Health Canada comments